The Week in Review: December 15 – December 22, 2017

Friday, December 22, 2017 News Recap: Eight Genotypes: Did you know that there are now 8 genotypes and 84 subtypes of HCV that have been identified?  On the one hand this is terrible news; but on the other, a study presented at AASLD 2017 found that Vosevi was effective against them all.  Eight Genotypes and 84 Subtypes of HCV. Telemedicine: Did you know that Project ECHO (Extension for Community Health Outcomes), a fast-growing international tele...

Is Project ECHO the Telemedicine Model That Healthcare Is Missing?

A fast-growing international program, Project ECHO uses telemedicine to help rural and remote providers learn from specialists to manage care for their complex patients. A telemedicine platform developed about 15 years ago in New Mexico is now helping thousands of doctors across the country learn from specialists and manage care for patients with complex conditions. Project ECHO (Extension for Community Health Outcomes) uses a hub-and-spoke model to co

The Week in Review: September 29 – October 6, 2017

Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease.  The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...

U.S.: Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment

Valerie Green is still waiting to be cured. The Delaware resident was diagnosed with hepatitis C more than two years ago, but she doesn’t qualify yet for the Medicaid program’s criteria for treatment with a new class of highly effective but pricey drugs. The recent approval of a less expensive drug that generally cures hepatitis C in just eight weeks may make it easier for more insurers and correctional facilities to expand treatment. The drug, Mavyret, i

The Week in Review: July 28 – August 4, 2017

Friday, August 4, 2017 Treatment: This last week saw the approval in the U.S. of AbbVie’s Mavyret, a pangenotypic also indicated as recuperation therapy for those with GT1 who have failed treatment with DAAs. U.S.: FDA approves Mavyret for Hepatitis C As well, the FDA has approved updated labeling for Epclusa to include use in patients co-infected with HIV. U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatmen...

Sask. doctor concerned about ‘shockingly low’ number of hepatitis C patients being treated

This spring, the province expanded coverage for new drugs that have a 95% cure rate An infectious disease specialist in Regina is trying to raise awareness about the availability of drugs that have a 95 per cent cure rate for hepatitis C. Dr. Alex Wong, who works for the Regina Qu'Appelle Health Region, said to his knowledge there is no official number for how many people are living with the disease in Saskatchewan, but he estimates the number at anywh

The Week in Review: July 7 – July 14, 2017

Friday, July 14, 2017 News Recap Local New measures boost addiction treatment access in Victoria New efforts to expand treatment for opioid users in Victoria are putting addiction specialists in hospital emergency departments and supporting family doctors who provide opioid substitution therapy for patients. The initiatives by Island Health and the Victoria Divisions of Family Practice are intended to dovetail with the work of the South Island Ra...

Hepatitis C: New hope for patients

A non-profit organisation is making headway in its initiative to develop drugs for neglected diseases to benefit those who can’t afford them. New Sunday Times speaks to two medical practitioners who are working towards making affordable Hepatitis C treatment available to local hospitals. OF the estimated 150 million people infected with chronic Hepatitis C around the world, approximately 75 per cent live in low- to middle-income countries. However, som

Coverage Denials Eyed in HCV Rx Nonstarts

From the "Tell me something I don't already know department"! Coverage denials by payors are the main factor in a dramatic rise in failure to start hepatitis C drug treatment over the past three years, according to new data released March 8 by Trio Health, which has collected real-world evidence on 15,000 HCV patients since the launch of the direct-acting antiviral agents (DAAs) in 2014. As of 2016, more than one-third of patients prescribed DAA treatm

London liver specialist urges people to get tested, treated, cured and move on with their lives because new drugs have a 98 per cent cure rate

The eradication of hepatitis C may be on the horizon. New, expensive drugs approved by the Ontario government mean new hope for those suffering from liver-destroying hepatitis C, a potentially fatal virus that many people don’t even know they have. The Ontario government has added six new hepatitis drugs to its Ontario Public Drug Programs that will help cure the 40 per cent of hepatitis sufferers who formerly were unable to access treatment. “It’s a v